Guangxi University of Chinese Medicine, Nanning 530200, China.
The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China.
J Healthc Eng. 2022 Mar 25;2022:3139929. doi: 10.1155/2022/3139929. eCollection 2022.
This study aims to investigate the clinical efficacy of plasma exchange in treating acute-on-chronic liver failure (ACLF) through meta-analysis.
PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang databases were searched using a computer for all relevant Chinese and English literature from 2000 to 2021 in each database. At the same time, a large number of related papers and materials were manually consulted. Randomized controlled trials of plasma exchange (PE, control group) and combined double plasma molecular absorption system (DPMAS + PE, observation group) for the treatment of ACLF were collected. Meta-analysis was performed with Stata16.0 software.
A total of 474 articles were retrieved, and 11 papers were finally included for research after screening. Meta-analysis results showed that the effective rate of treatment in the experimental group was significantly higher than that in the control group. At the same time, the observation group's prothrombin activity (PTA) level was better than that of the control group after treatment. After treatment, there was no significant difference in prothrombin time (PT) and international normalized ratio (INR) between the two groups. In addition, after treatment, the alanine aminotransferase (ALT) level of the observation group was significantly lower than that of the control group. However, TBIL levels and albumin (ALB) levels did not change significantly between the two groups. Regarding blood routine indexes, there were no significant changes in creatinine (Cr) levels and platelet counts (PLT) in the two groups after treatment, but hemoglobin (HGB) levels in the observation group were significantly lower than those in the control group.
DPMAS combined with plasma exchange therapy can improve liver function, coagulation function, and blood routine level of ACLF patients and increase the effective rate of treatment. It is an effective treatment for acute-on-chronic liver failure.
本研究通过荟萃分析探讨血浆置换治疗慢加急性肝衰竭(ACLF)的临床疗效。
计算机检索 2000 年至 2021 年各数据库中关于血浆置换(PE,对照组)和双重血浆分子吸附系统(DPMAS+PE,观察组)治疗 ACLF 的随机对照试验的中文和英文文献,同时手工查阅大量相关文献和资料。
共检索到 474 篇文章,筛选后最终纳入 11 篇文献进行研究。Meta 分析结果显示,观察组治疗有效率显著高于对照组。同时,观察组治疗后的凝血酶原活动度(PTA)水平优于对照组。治疗后两组凝血酶原时间(PT)和国际标准化比值(INR)无显著差异。此外,观察组治疗后丙氨酸氨基转移酶(ALT)水平明显低于对照组。但两组总胆红素(TBIL)和白蛋白(ALB)水平无明显变化。血常规指标方面,两组治疗后肌酐(Cr)水平和血小板计数(PLT)无明显变化,但观察组血红蛋白(HGB)水平明显低于对照组。
DPMAS 联合血浆置换治疗可改善 ACLF 患者的肝功能、凝血功能和血常规水平,提高治疗有效率,是治疗急性肝衰竭的有效方法。